Quadruplet daratumumab in combination with bortezomib, lenalidomide, and dexamethasone as front-line regimen improved clinical outcomes in high-risk myeloma patients in China: a multi-centered prospective real-world study.

BMC Cancer · 2026 · PMC13094279 · PMID 41808058

Europe PMC DOI

hedged sentences

0.4320

closest p · 8.6× alpha

0.4320

boldest claim

The sentences

did not reach statistical significanceP = 0.432not close (p > 0.1)

82.0%,HR 0.30,95%CI 0.27–1.26), although the differences did not reach statistical significance ( P = 0.432 and P = 0.098, respectively) (Fig.

also in 111,027 other papers

showed a trendno p-value reported

Among transplant-ineligible patients, 1-year PFS showed a trend favoring D-VRd over VRd (88% vs. 81%; HR 0.56, 95% CI 0.32–0.99).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.